185 related articles for article (PubMed ID: 25156775)
1. Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer.
He DX; Gu XT; Li YR; Jiang L; Jin J; Ma X
FEBS J; 2014 Oct; 281(20):4718-30. PubMed ID: 25156775
[TBL] [Abstract][Full Text] [Related]
2. MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway.
Jiang L; He D; Yang D; Chen Z; Pan Q; Mao A; Cai Y; Li X; Xing H; Shi M; Chen Y; Bruce IC; Wang T; Jin L; Qi X; Hua D; Jin J; Ma X
FEBS Lett; 2014 May; 588(11):2009-15. PubMed ID: 24786471
[TBL] [Abstract][Full Text] [Related]
3. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract][Full Text] [Related]
4. A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer.
He DX; Gu XT; Jiang L; Jin J; Ma X
Mol Pharmacol; 2014 Nov; 86(5):536-47. PubMed ID: 25159093
[TBL] [Abstract][Full Text] [Related]
5. Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.
Lv J; Fu Z; Shi M; Xia K; Ji C; Xu P; Lv M; Pan B; Dai L; Xie H
Biomed Pharmacother; 2015 Feb; 69():162-9. PubMed ID: 25661353
[TBL] [Abstract][Full Text] [Related]
6. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
7. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
8. Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel.
Wu H; Huang M; Lu M; Zhu W; Shu Y; Cao P; Liu P
Cancer Chemother Pharmacol; 2013 May; 71(5):1159-71. PubMed ID: 23423488
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1.
Li XJ; Ji MH; Zhong SL; Zha QB; Xu JJ; Zhao JH; Tang JH
Arch Med Res; 2012 Oct; 43(7):514-21. PubMed ID: 23085450
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.
Yang G; Wu D; Zhu J; Jiang O; Shi Q; Tian J; Weng Y
Oncol Rep; 2013 Aug; 30(2):877-89. PubMed ID: 23760062
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer.
Tang JT; Wang JL; Du W; Hong J; Zhao SL; Wang YC; Xiong H; Chen HM; Fang JY
Carcinogenesis; 2011 Aug; 32(8):1207-15. PubMed ID: 21665895
[TBL] [Abstract][Full Text] [Related]
13. HS3ST2 modulates breast cancer cell invasiveness via MAP kinase- and Tcf4 (Tcf7l2)-dependent regulation of protease and cadherin expression.
Vijaya Kumar A; Salem Gassar E; Spillmann D; Stock C; Sen YP; Zhang T; Van Kuppevelt TH; Hülsewig C; Koszlowski EO; Pavao MS; Ibrahim SA; Poeter M; Rescher U; Kiesel L; Koduru S; Yip GW; Götte M
Int J Cancer; 2014 Dec; 135(11):2579-92. PubMed ID: 24752740
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer.
He DX; Gu F; Gao F; Hao JJ; Gong D; Gu XT; Mao AQ; Jin J; Fu L; Ma X
Sci Rep; 2016 Apr; 6():24706. PubMed ID: 27094684
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development.
Zhang S; Hao J; Xie F; Hu X; Liu C; Tong J; Zhou J; Wu J; Shao C
Carcinogenesis; 2011 Aug; 32(8):1183-9. PubMed ID: 21665894
[TBL] [Abstract][Full Text] [Related]
16. The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2).
Hu H; Li S; Cui X; Lv X; Jiao Y; Yu F; Yao H; Song E; Chen Y; Wang M; Lin L
J Biol Chem; 2013 Apr; 288(16):10973-85. PubMed ID: 23436656
[TBL] [Abstract][Full Text] [Related]
17. Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4.
Feng X; Zhao L; Gao S; Song X; Dong W; Zhao Y; Zhou H; Cheng L; Miao X; Jia L
Gene; 2016 Mar; 578(2):232-41. PubMed ID: 26701615
[TBL] [Abstract][Full Text] [Related]
18. Role of ferritin alterations in human breast cancer cells.
Shpyleva SI; Tryndyak VP; Kovalchuk O; Starlard-Davenport A; Chekhun VF; Beland FA; Pogribny IP
Breast Cancer Res Treat; 2011 Feb; 126(1):63-71. PubMed ID: 20390345
[TBL] [Abstract][Full Text] [Related]
19. Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.
Chekhun VF; Lukyanova NY; Burlaka CA; Bezdenezhnykh NA; Shpyleva SI; Tryndyak VP; Beland FA; Pogribny IP
Int J Oncol; 2013 Nov; 43(5):1481-6. PubMed ID: 23969999
[TBL] [Abstract][Full Text] [Related]
20. miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer.
Chen B; Tang H; Liu X; Liu P; Yang L; Xie X; Ye F; Song C; Xie X; Wei W
Cancer Lett; 2015 Jan; 356(2 Pt B):410-7. PubMed ID: 25304371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
